CXI Healthcare Technology Group Limited (KOSDAQ:900120)
South Korea · Delayed Price · Currency is KRW 1,955.00
+70.00 (3.71%)
At close: May 11, 2026
KOSDAQ:900120 Income Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Operating Revenue | 51,446 | 57,636 | 69,420 | 71,617 | 101,376 | 104,593 |
Other Revenue | -0 | - | - | - | 0 | - |
| 51,446 | 57,636 | 69,420 | 71,617 | 101,376 | 104,593 | |
Revenue Growth (YoY) | -20.11% | -16.97% | -3.07% | -29.35% | -3.08% | 64.96% |
Cost of Revenue | 37,134 | 40,320 | 39,544 | 43,405 | 73,018 | 82,777 |
Gross Profit | 14,311 | 17,316 | 29,876 | 28,213 | 28,358 | 21,816 |
Selling, General & Admin | 7,953 | 7,739 | 5,326 | 10,682 | 12,638 | 12,037 |
Research & Development | - | -2.91 | 4,939 | 9,750 | 9,317 | 3,818 |
Other Operating Expenses | 17.68 | 21.23 | 136.77 | 144.34 | 152.96 | 404.64 |
Operating Expenses | 7,956 | 7,616 | 11,223 | 21,077 | 22,067 | 17,287 |
Operating Income | 6,355 | 9,700 | 18,653 | 7,136 | 6,292 | 4,529 |
Interest Expense | -6.19 | -4.14 | -5.06 | -2.86 | -53.79 | -17.39 |
Interest & Investment Income | 96.67 | 191.67 | 257.51 | 230.33 | 141.06 | 324.04 |
Earnings From Equity Investments | - | - | - | 235.78 | - | - |
Currency Exchange Gain (Loss) | -204.44 | 36.09 | -128.15 | 62.53 | -142.41 | 208.78 |
Other Non Operating Income (Expenses) | 19.51 | -12.36 | 5.39 | 27.72 | 235.82 | 41.7 |
EBT Excluding Unusual Items | 6,260 | 9,911 | 18,783 | 7,689 | 6,472 | 5,086 |
Gain (Loss) on Sale of Investments | 3,416 | 3,847 | 6,860 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | 3,697 | - | -491.11 | - |
Asset Writedown | - | - | - | -161.3 | - | - |
Other Unusual Items | -0 | 7.95 | 2.42 | - | - | - |
Pretax Income | 9,677 | 13,766 | 29,342 | 7,528 | 5,981 | 5,086 |
Income Tax Expense | 1,026 | 1,026 | - | - | - | - |
Earnings From Continuing Operations | 8,651 | 12,741 | 29,342 | 7,528 | 5,981 | 5,086 |
Minority Interest in Earnings | - | - | 6.93 | 0.02 | 0.25 | 11.71 |
Net Income | 8,651 | 12,741 | 29,349 | 7,528 | 5,981 | 5,098 |
Net Income to Common | 8,651 | 12,741 | 29,349 | 7,528 | 5,981 | 5,098 |
Net Income Growth | -63.36% | -56.59% | 289.87% | 25.86% | 17.33% | - |
Shares Outstanding (Basic) | 33 | 1 | 1 | 2 | 2 | 2 |
Shares Outstanding (Diluted) | 33 | 1 | 1 | 2 | 2 | 2 |
Shares Change (YoY) | 59.75% | 17.38% | -79.37% | - | 10.22% | 0.77% |
EPS (Basic) | 258.67 | 21450.03 | 58000.07 | 3116.94 | 2476.62 | 2291.11 |
EPS (Diluted) | 258.67 | 21450.03 | 58000.07 | 3069.47 | 2400.00 | 2291.11 |
EPS Growth | -76.89% | -63.02% | 1789.58% | 27.89% | 4.75% | - |
Free Cash Flow | -187,972 | 40,180 | 43,666 | 31,597 | 35,979 | -196,165 |
Free Cash Flow Per Share | -5620.55 | 67646.00 | 86293.20 | 12883.73 | 14670.13 | -88158.94 |
Gross Margin | 27.82% | 30.04% | 43.04% | 39.39% | 27.97% | 20.86% |
Operating Margin | 12.35% | 16.83% | 26.87% | 9.96% | 6.21% | 4.33% |
Profit Margin | 16.81% | 22.11% | 42.28% | 10.51% | 5.90% | 4.87% |
Free Cash Flow Margin | -365.38% | 69.71% | 62.90% | 44.12% | 35.49% | -187.55% |
EBITDA | 32,492 | 33,142 | 43,296 | 31,116 | 32,004 | 23,198 |
EBITDA Margin | 63.16% | 57.50% | 62.37% | 43.45% | 31.57% | 22.18% |
D&A For EBITDA | 26,137 | 23,442 | 24,642 | 23,980 | 25,713 | 18,669 |
EBIT | 6,355 | 9,700 | 18,653 | 7,136 | 6,292 | 4,529 |
EBIT Margin | 12.35% | 16.83% | 26.87% | 9.96% | 6.21% | 4.33% |
Effective Tax Rate | 10.60% | 7.45% | - | - | - | - |
Advertising Expenses | - | 839.82 | 675.56 | 1,284 | 1,195 | 1,542 |